Peter Ostler

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Douglas Brand, Alison Tree, Peter Ostler et al. · The Lancet Oncology · 2019 · 536 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer

Peter Hoskin, Ana M. Rojas, Peter Bownes et al. · Radiotherapy and Oncology · 2012 · 494 citations

Medicine, Oncology, Radiation Oncology +17

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

Karim Fizazi, Josep M. Piulats, M. Neil Reaume et al. · New England Journal of Medicine · 2023 · 414 citations · Full text

Medicine, Oncology, Pharmacology +15

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial

Christopher Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2020 · 403 citations · Full text

Medicine, Radiation Oncology, Urology +11

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Alison Tree, Peter Ostler, H. van der Voet et al. · The Lancet Oncology · 2022 · 303 citations · Full text

Medicine, Oncology, Radiation Oncology +16